Artivion outlines 2026 revenue of $484M to $492M while preparing January 2027 NEXUS launch

• "In the third quarter, we delivered total constant currency revenue growth of 9% and adjusted EBITDA decline of 8% year-over-year." (Chairman, President & CEO James Mackin)
• "Stent graft revenues grew 12% on a constant currency basis in the third quarter" and "U.S. AMDS set sales remain challenged" with management attributing it to "the upfront $100,000 investment for starter set" and calling the dynamic "administrative and transient." (Chairman, President & CEO Mackin)
• "We believe our preparations for U.S. commercial launch early next year are progressing well" and the U.S. launch "is expected in January of 2027" as the company focuses on "expanding manufacturing capacity and building inventory" and "augmenting our U.S. sales team." (Chairman, President & CEO Mackin)
• "Total revenues were $123.8 million for the third quarter of 2026, up 9% compared to Q3 of 2025." (EVP, COO, CFO & Treasurer Lance Berry)

Outlook

• "We are narrowing our expectation for adjusted constant currency growth to now be between 8% to 10% for the full year 2026, representing a reported revenue range of $484 million to $492 million." (EVP, COO, CFO & Treasurer Berry)
• "We are also narrowing our full year 2026 adjusted EBITDA to be in the range of $93 million to $98 million." (EVP, COO, CFO & Treasurer Berry)
• "The guidance assumes inconsequential revenue from U.S. NEXUS sales in 2026" for an "anticipated January 1, 2027 U.S. launch." (EVP, COO, CFO & Treasurer Berry)
• On 2027 headwinds tied to PerClot, management stated, "we are anticipating a 2 percentage point revenue growth headwind and a 4 percentage point EBITDA growth headwind" from completion of the Baxter agreement. (EVP, COO, CFO & Treasurer Berry)

Financial Results

• "Adjusted EBITDA decreased approximately 8% from $24.6 million to $22.5 million" and "Adjusted EBITDA margin was 18.2%" with the decline "primarily driven by costs associated with the Endospan business and gross margin" impacts from "mix and investments in the On-X and NEXUS manufacturing facilities." (EVP, COO, CFO & Treasurer Berry)
• "Q3 gross margins were 61.4%, a decrease from 65.6%" as "favorable pricing was more than offset by unfavorable mix and some higher costs" during production ramp. (EVP, COO, CFO & Treasurer Berry)
• "Free cash flow was negative $17.6 million" and management attributed the swing to "$13.3 million for a portion of the AMDS PMA milestone payment" and "approximately $2 million of Endospan-related integration expenses." (EVP, COO, CFO & Treasurer Berry)
• Balance sheet and leverage update included: "we had approximately $48.4 million in cash" and "$363.8 million in debt" and "our net leverage ratio was 3.5x" reflecting the AMDS milestone payment. (EVP, COO, CFO & Treasurer Berry)

Q&A

• John McAulay, Stifel: Asked about implied Q4 deceleration and 2027 impacts; Chairman, President & CEO Mackin: "In Q4, it flips to a headwind, at least 1 percentage point headwind" on FX, and said Q3 tissue outperformance was "timing" expected to "reverse in Q4," adding on PerClot: "take 2 percentage points off" revenue growth assumptions and "take 4 percentage points off" EBITDA growth assumptions.
• John McAulay, Stifel: Pressed on AMDS set-sale headwinds; Chairman, President & CEO Mackin: "the bottlenecks for these starter sets is really an administrative problem" tied to "$100,000" and said, "we continue to see the implants doing better in Q3 than they were -- excuse me, in Q4 than Q3."
• William Plovanic, Canaccord: Challenged stent-graft growth trajectory; EVP, COO, CFO & Treasurer Berry: "core stent graft certainly in some of the quarters this year is below the kind of mid-teens" but "we still see that as definitely a double-digit growth business"; Chairman, President & CEO Mackin: "we thought getting through the VACs" would be hardest, but "we're not having any problems getting through the VAC" and the issue is "getting the PO actually in the $100,000."
• Shaymus Contorno, Oppenheimer: Asked how NEXUS ramps post-January; Chairman, President & CEO Mackin: "This is going to roll out in a typical fashion" and contrasted AMDS by saying, "we don't have the starter set issue" and "They don't have to buy anything upfront."
• Michael Sarcone, Jefferies: Asked what isn’t resonating for AMDS and gross margin trajectory; Chairman, President & CEO Mackin: highlighted reimbursement messaging and said, "It's amazing to me that hospitals more and more -- like just hospitals don't -- aren't aware of the information"; EVP, COO, CFO & Treasurer Berry: on 2027 margin, "we're not getting into details on '27" and called current pressures "all timing" plus "a few period charges this quarter."

Sentiment Analysis

• Analysts were slightly negative to pressing on AMDS conversion friction, growth cadence, and margin visibility, including pointed framing such as "how do you get the dam to break on this?" (William Plovanic, Canaccord).
• Management tone was slightly positive in prepared remarks and more defensive/contained in Q&A on 2027 details, including "we're not going to get into a bunch of details on '27" and "we're not getting into details on '27." (Chairman, President & CEO Mackin; EVP, COO, CFO & Treasurer Berry)
• Versus the prior quarter, management language moved from expectations of PMA-driven acceleration to emphasizing administrative hurdles: Q2 said PMA "obviates the lengthy IRB review process" and "we expect to accelerate new account conversion," while Q3 said PMA "didn't do anything for the administrative burden" of obtaining POs. (Chairman, President & CEO Mackin)

Quarter-over-Quarter Comparison

• Guidance framing tightened: Q2 kept 2026 growth at "between 7% to 11%" and EBITDA "$92 million to $99 million," while Q3 narrowed to "between 8% to 10%" and "$93 million to $98 million." (EVP, COO, CFO & Treasurer Berry)
• AMDS commercialization narrative shifted from Q2 confidence that PMA would help set sales to Q3 acknowledgment that "U.S. AMDS set sales remain challenged" and that the barrier is the "$100,000" starter set purchase order process. (Chairman, President & CEO Mackin)
• Q2 featured profitability growth ("adjusted EBITDA growth of 7%"), while Q3 emphasized launch and manufacturing investments coinciding with an EBITDA decline. (Chairman, President & CEO Mackin)

Risks and Concerns

• Starter-set purchasing friction remained central: management said the AMDS set-sale issue is "an administrative problem" because hospitals must "pay $100,000 to buy the starter set" and that "it's different at every hospital." (Chairman, President & CEO Mackin)
• Margin and cash flow pressures were tied to ramp and acquisition integration: management cited "higher costs" in manufacturing ramp, Endospan-related costs, and milestone payments impacting free cash flow classification. (EVP, COO, CFO & Treasurer Berry)
• A defined 2027 growth headwind was reiterated: "completion of our PerClot agreement with Baxter" creating a "2 percentage point" revenue growth headwind and "4 percentage point" EBITDA growth headwind. (EVP, COO, CFO & Treasurer Berry)

Final Takeaway

Management described a Q3 defined by 9% constant-currency revenue growth alongside lower adjusted EBITDA, while keeping strategy centered on aortic platforms: increasing AMDS implants despite starter-set purchasing friction, building inventory and commercial readiness for a January 2027 NEXUS launch, and continuing ARTIZEN enrollment with upcoming early-patient data presentation. For 2026, leadership narrowed full-year growth and EBITDA ranges and highlighted a specific 2027 headwind tied to the PerClot transition.

Read the full Earnings Call Transcript

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.